{"preliminary_commentary":{"by_channel":{"x_thread":6,"podcast":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03869190\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT03869190","nct_id":"NCT03869190","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03869190. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.\n\nEnrollment is closed.","label":"Atezolizumab for mUC Cohort (Stage 1)","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Niraparib for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and magrolimab (Hu5F9-G4) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Magrolimab for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Tiragolumab for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Tocilizumab for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + RO7122290 for mUC Cohort (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2)","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.","label":"Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2)","type":"EXPERIMENTAL"},{"description":"Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.","label":"Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 1","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.","label":"Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 2","type":"EXPERIMENTAL"},{"description":"Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.","label":"Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 1","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.","label":"Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 2","type":"EXPERIMENTAL"},{"description":"Participants will receive 3 cycles of Atezolizumab, Cisplatin, and Gemcitabine pre-surgery and 14 cycles of Atezolizumab only post-surgery.","label":"Cisplatin-eligible MIBC Cohort 3 Arm 1","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive Atezolizumab, Tiragolumab (Tira), Cisplatin and Gemcitabine for 3 cycles pre-surgery and 14 cycles of Atezolizumab and Tiragolumab (Tira) post-surgery.","label":"Cisplatin-eligible MIBC Cohort 3 Arm 2","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas"],"completion_date":{"date":"2025-12-22","type":"ACTUAL"},"conditions":["Urothelial Carcinoma","Bladder Cancer"],"enrollment":{"count":272,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Enfortumab Vedotin","otherNames":[],"type":"DRUG"},{"name":"Niraparib","otherNames":[],"type":"DRUG"},{"name":"Magrolimab (Hu5F9-G4)","otherNames":[],"type":"DRUG"},{"name":"Tiragolumab","otherNames":[],"type":"DRUG"},{"name":"Sacituzumab Govitecan","otherNames":[],"type":"DRUG"},{"name":"Tocilizumab","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-03","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-10-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Stage 1 mUC Cohorts: Objective Response Rate (ORR)","timeFrame":"Up to 61.5 months"},{"measure":"MIBC Cohorts: Pathological Complete Response (pCR)","timeFrame":"Up to 17.8 months"}],"references":[{"citation":"Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Flechon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798.","pmid":"37651261","type":"DERIVED"}],"start_date":{"date":"2019-06-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","url":"https://clinicaltrials.gov/study/NCT03869190"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03869190"}